{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:43:03Z","timestamp":1740184983567,"version":"3.37.3"},"reference-count":38,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T00:00:00Z","timestamp":1726531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Co","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jacadv.2024.101335","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T01:00:23Z","timestamp":1729126823000},"page":"101335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Apixaban and Limiting Aspirin for Patients With Atrial Fibrillation, Percutaneous Coronary Intervention, and\u00a0Multimorbidity"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7792-2837","authenticated-orcid":false,"given":"Konstantin A.","family":"Krychtiuk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Wojdyla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun G.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Aronson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen P.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2024.101335_bib1","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics-2023 update: a report from the American heart association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2024.101335_bib2","doi-asserted-by":"crossref","first-page":"k1453","DOI":"10.1136\/bmj.k1453","article-title":"Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study","volume":"361","author":"Staerk","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jacadv.2024.101335_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024964","article-title":"Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography","volume":"6","author":"Kralev","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jacadv.2024.101335_bib4","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.121.011232","article-title":"Atrial fibrillation and coronary artery disease: a long-term perspective on the need for combined antithrombotic therapy","volume":"14","author":"Fanaroff","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacadv.2024.101335_bib5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2024.101335_bib6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2024.101335_bib7","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American college of Cardiology\/American heart association joint committee on clinical practice guidelines","volume":"79","author":"Writing Committee","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2024.101335_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS Guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2024.101335_bib9","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy","volume":"139","author":"van Rein","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2024.101335_bib10","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.101335_bib11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ahj.2016.11.008","article-title":"Multimorbidity and the risk of hospitalization and death in atrial fibrillation: a population-based study","volume":"185","author":"Chamberlain","year":"2017","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacadv.2024.101335_bib12","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jacc.2021.10.037","article-title":"Management of atrial fibrillation in patients 75 Years and older: JACC state-of-the-art review","volume":"79","author":"Volgman","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacadv.2024.101335_bib13","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.amjmed.2020.03.045","article-title":"Comparison of dabigatran plus a P2Y(12) inhibitor with warfarin-based triple therapy across body mass index in RE-DUAL PCI","volume":"133","author":"De Caterina","year":"2020","journal-title":"Am J Med"},{"key":"10.1016\/j.jacadv.2024.101335_bib14","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ehjcvp\/pvaa135","article-title":"Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI","volume":"8","author":"Costa","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacadv.2024.101335_bib15","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.amjcard.2019.11.029","volume":"125","author":"Ten Berg","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacadv.2024.101335_bib16","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/j.jcin.2019.07.059","article-title":"Dabigatran dual therapy versus warfarin triple therapy post-PCI in patients with atrial fibrillation and diabetes","volume":"12","author":"Maeng","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacadv.2024.101335_bib17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jamacardio.2022.1166","article-title":"Apixaban or warfarin and aspirin or placebo after acute coronary syndrome or percutaneous coronary intervention in patients with atrial fibrillation and prior stroke: a post hoc analysis from the AUGUSTUS trial","volume":"7","author":"Bahit","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2024.101335_bib18","article-title":"Efficacy and safety of antithrombotic therapy in patients with atrial fibrillation, recent acute coronary syndrome, or percutaneous coronary intervention and a history of heart failure: insights from the AUGUSTUS trial","volume":"10","author":"Fudim","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2024.101335_bib19","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jcin.2019.05.050","article-title":"Renal function and outcomes with dabigatran dual antithrombotic therapy in atrial fibrillation patients after PCI","volume":"12","author":"Hohnloser","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacadv.2024.101335_bib20","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1161\/CIRCULATIONAHA.120.051020","article-title":"Apixaban or vitamin K antagonists and aspirin or placebo according to kidney function in patients with atrial fibrillation after acute coronary syndrome or percutaneous coronary intervention: insights from the AUGUSTUS trial","volume":"143","author":"Hijazi","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2024.101335_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ahj.2018.03.001","volume":"200","author":"Lopes","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacadv.2024.101335_bib22","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"10.1016\/j.jacadv.2024.101335_bib23","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamacardio.2019.6175","article-title":"Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis","volume":"5","author":"Lopes","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacadv.2024.101335_bib24","doi-asserted-by":"crossref","first-page":"E102","DOI":"10.1002\/ccd.28535","article-title":"A\u00a0systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"96","author":"Sullivan","year":"2020","journal-title":"Cathet Cardiovasc Interv"},{"key":"10.1016\/j.jacadv.2024.101335_bib25","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.115.018544","article-title":"Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation","volume":"133","author":"Piccini","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2024.101335_bib26","doi-asserted-by":"crossref","first-page":"i2868","DOI":"10.1136\/bmj.i2868","article-title":"Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial","volume":"353","author":"Jaspers","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jacadv.2024.101335_bib27","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ahj.2021.12.017","article-title":"Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: a comprehensive analysis of high-risk subgroups","volume":"247","author":"Gencer","year":"2022","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacadv.2024.101335_bib28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ahj.2018.09.017","article-title":"Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: insights from the ARISTOTLE trial","volume":"208","author":"Alexander","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacadv.2024.101335_bib29","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/s12916-020-01870-w","article-title":"Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial","volume":"18","author":"Wilkinson","year":"2020","journal-title":"BMC Med"},{"issue":"4","key":"10.1016\/j.jacadv.2024.101335_bib30","first-page":"279","article-title":"Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial","volume":"149","author":"Joosten","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2024.101335_bib31","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2024.101335_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.28500","article-title":"Outcomes and safety of very-low-dose edoxaban in frail patients with atrial fibrillation in the ELDERCARE-AF randomized clinical trial","volume":"5","author":"Akashi","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacadv.2024.101335_bib33","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/jgs.14868","article-title":"Effect of chronic diseases and multimorbidity on survival and functioning in elderly adults","volume":"65","author":"Rizzuto","year":"2017","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.jacadv.2024.101335_bib34","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(12)62167-9","article-title":"Frailty in elderly people","volume":"381","author":"Clegg","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacadv.2024.101335_bib35","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.120.050438","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a north American perspective: 2021 update","volume":"143","author":"Angiolillo","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacadv.2024.101335_bib36","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacadv.2024.101335_bib37","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chron Dis"},{"key":"10.1016\/j.jacadv.2024.101335_bib38","first-page":"236","article-title":"Measuring frailty: developing and testing the GFI (Groningen frailty indicator)","volume":"41","author":"Steverink","year":"2001","journal-title":"Gerontol"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X2400615X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X2400615X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T03:17:40Z","timestamp":1737429460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X2400615X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2772963X2400615X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2024.101335","relation":{},"ISSN":["2772-963X"],"issn-type":[{"type":"print","value":"2772-963X"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apixaban and Limiting Aspirin for Patients With Atrial Fibrillation, Percutaneous Coronary Intervention, and\u00a0Multimorbidity","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2024.101335","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101335"}}